SCHEMBL6832069

SCHEMBL6832069

COc1c(N2CCN(C)C(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.75
ALDH1A1 P00352 5/20 0.75
KCNH2 Q12809 5/20 0.75
HPGD P15428 4/20 0.75
TDP1 Q9NUW8 3/20 0.75
POLB P06746 3/20 0.75
LMNA P02545 2/20 0.75
HSD17B10 Q99714 2/20 0.75
OPRM1 P35372 2/20 0.75
PRKD3 O94806 1/20 0.75
ALOX15 P16050 1/20 0.75
CLK2 P49760 1/20 0.75
CLK4 Q9HAZ1 1/20 0.75
CYP2C19 P33261 1/20 0.69
L3MBTL1 Q9Y468 1/20 0.69
NPSR1 Q6W5P4 1/20 0.67
ATM Q13315 1/20 0.65
MEN1 O00255 1/20 0.62
KMT2A Q03164 1/20 0.62
CHRM2 P08172 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29351326 1.00 KDM4E (0.75) KDM4EALDH1A1KCNH2HPGDTDP1
Hydrochloric Acid SCHEMBL9773650 0.99 KDM4E (0.74) KDM4EALDH1A1KCNH2HPGDTDP1
SCHEMBL13841372 0.93 KDM4E (0.68) KDM4EALDH1A1KCNH2HPGDTDP1
SCHEMBL9634911 0.90 KDM4E (0.61) KDM4EALDH1A1KCNH2HPGDTDP1
SCHEMBL2738948 0.90 KDM4E (0.71) KDM4EALDH1A1KCNH2HPGDTDP1
SCHEMBL30564254 0.90 KDM4E (0.81) KDM4EALDH1A1KCNH2HPGDTDP1
SCHEMBL2738950 0.89 KDM4E (0.70) KDM4EALDH1A1KCNH2HPGDTDP1
SCHEMBL10109100 0.89 KDM4E (0.72) KDM4EALDH1A1KCNH2HPGDTDP1
SCHEMBL12665472 0.89 KCNH2 (0.72) KDM4EALDH1A1KCNH2HPGDTDP1
Hydrochloric Acid SCHEMBL9773974 0.88 KDM4E (0.71) KDM4EALDH1A1KCNH2HPGDTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0241206-A2 Quinoline-3-carboxylic acid derivatives, their preparation and use Sankyo Company Limited (JP) 1987-10-14 EP claimed
US-20110124597-A1 BORON CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. (US) 2011-05-26 US disclosed
WO-2008097546-A2 COMPOUNDS THAT INHIBIT CHOLINESTERASE COLUCID PHARMACEUTICALS, INC. (US) 2008-08-14 WO disclosed
US-7250413-B2 C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes CUMBRE PHARMACEUTICALS INC. (US) 2007-07-31 US disclosed
WO-2004101547-A1 PURIFICATION METHODS OF GATIFLOXACIN AND A NOVEL FORM OF GATIFLOXACIN HETERO DRUGS LIMITED (IN) 2004-11-25 WO disclosed
US-4997943-A Bactericides SANKYO COMPANY LIMITED (JP) 1991-03-05 US disclosed
EP-0241206-A2 Quinoline-3-carboxylic acid derivatives, their preparation and use Sankyo Company Limited (JP) 1987-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124597-A1 BORON CONTAINING SMALL MOLECULES BCL6B, BCL6, BLVRB KDM4E 3691/4885ALDH1A1 4730/4885KCNH2 4184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.